Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genetic Analysis AS's earnings before interest and taxes (EBIT) for the
three
months ended in Mar. 2026 was kr-3.72 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr-10.18 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Genetic Analysis AS's annualizedROC % for the quarter that ended in Mar. 2026 was -44.81%.
Genetic Analysis AS's annualizedROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -388.46%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Genetic Analysis AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -29.67%.
Genetic Analysis AS (XSAT:GEAN) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Genetic Analysis AS's annualizedROC % for the quarter that ended in Mar. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Genetic Analysis AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genetic Analysis AS EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Genetic Analysis AS's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-10.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genetic Analysis AS (XSAT:GEAN) has a EBIT of kr-10.18 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Genetic Analysis AS.
Is Genetic Analysis AS's EBIT too high?
Genetic Analysis AS's current EBIT is kr-10.18 Mil. Overall, Genetic Analysis AS has a GF Score™ of 34/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genetic Analysis AS's EBIT compare to TMO and DHR?
Genetic Analysis AS's EBIT of kr-10.18 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Diagnostics & Research company?
A good EBIT depends on the Medical Diagnostics & Research industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Genetic Analysis AS. Genetic Analysis AS's current EBIT is kr-10.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genetic Analysis AS stock overvalued right now?
Based on GuruFocus' analysis, Genetic Analysis AS (XSAT:GEAN) is currently considered Modestly Overvalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.66 — trading 22.2% above its estimated fair value. The current EBIT is kr-10.18 Mil. Genetic Analysis AS's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Genetic Analysis AS (XSAT:GEAN), the current EBIT is kr-10.18 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genetic Analysis AS (XSAT:GEAN) Overvalued in 2026?
Based on GuruFocus' analysis, Genetic Analysis AS stock appears to be overvalued.
The current stock price of kr0.66 is trading 22.2% above its estimated GF Value™ of kr0.54.
GuruFocus considers Genetic Analysis AS to be Modestly Overvalued.
Key valuation signals for XSAT:GEAN:
EBIT: kr-10.18 Mil
GF Value™: kr0.54 vs. price of kr0.66 (22.2% above fair value)
No single metric tells the full story. See the XSAT:GEAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients. Geographically, it operates in the USA, Europe, and the Rest of the world. Geographically, the company sells products in the USA, Europe, and the rest of the world. The majority of its revenue is generated from the USA. The GA-map technology platform and product portfolio are currently used across three main market segments: Clinical diagnostics, research (academic and industry), and Consumer Health.
34GF Score
Get the complete analysis for XSAT:GEAN
EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:GEAN has been successfully added to your 
